| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
Bromodomain inhibitor that affects the reading of acetylation marks, thereby influencing transcription factor accessibility and could impact KLF14 activity indirectly. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
MEK inhibitor that could influence pathways upstream of KLF14, altering its transcriptional activity. | ||||||
Chaetocin | 28097-03-2 | sc-200893 | 200 µg | $120.00 | 5 | |
Disrupts hypoxia-inducible factor (HIF) pathways, which may intersect with KLF14's role in metabolic regulation. | ||||||
GW 9662 | 22978-25-2 | sc-202641 | 5 mg | $68.00 | 30 | |
PPARγ antagonist that can modulate adipogenic pathways, likely influencing KLF14 function given its role in adipose tissue distribution. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor that could interfere with stress and inflammatory signaling pathways, possibly affecting KLF14's regulatory roles. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Another PI3K inhibitor that could modify signaling cascades related to KLF14's activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
ROCK inhibitor that may alter cytoskeletal organization and related signaling, potentially impacting KLF14's cellular context. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor that alters cellular growth pathways, which could have downstream effects on KLF14's transcriptional control. | ||||||
Wnt-C59 | 1243243-89-1 | sc-475634 sc-475634A sc-475634B | 5 mg 10 mg 50 mg | $210.00 $320.00 $1250.00 | 1 | |
Wnt pathway inhibitor that could modify cellular differentiation pathways intersecting with KLF14's regulatory scope. | ||||||